Iktos’ mission

MS Ecole Polytechnique Paris and AgroParisTech. 20+ years experience in pharma R&D, strategic consulting and entrepreneurship in biotech.

Co-founder and CEO, Yann leads the development of Iktos with his knowledge of the pharmaceutical industry and a broad understanding of methods, approaches and tools of data science.

PhD in organometallic chemistry from University of Geneva. Medicinal chemist, skilled data scientist.

Co-founder and CSO, Quentin plays a key role in the strategic steering of Iktos’s R&D and portfolio development and supervision of project delivery for partners and customers.

PhD in Artificial Intelligence. Several years experience in software development and R&D. Contributed to the emerging data science field by creating distributed computation platform for Big Data processing.

Co-founder and CTO at Iktos, Nicolas leads the technological developments of the company.

MBA from New York University (Sterne School of Business) and PhD in organic chemistry from MIT, USA.

He brings an exceptional professional background with unvaluable experience in pharmaceutical research, investment and company leadership. He is the author of numerous publications in prestigious scientific journals and has filed over 20 patents during his career.

Roman also serves as Chairman of HDAX Therapeutics, and a Board Member at ReColony.

Ph.D. in Pharmaceutical Sciences from the University of Lausanne, Switzerland.

Bertrand is the CEO of Debiopharm and Senior Vice-Chairman of the Life Science activities of Après-demain. His work in various roles has contributed to two blockbuster therapies for cancer patients, oxaliplatin and triptorelin, along with a potential 3rd blockbuster drug currently in phase III research in Head & Neck cancer with an international partner.

Ph.D. in Biochemistry and Molecular Genetics from the University of Oxford.

Nadiya joined M Ventures Biotechnology team covering Healthcare and Life Sciences investments as an Associate in 2021. She has strong experience in strategy and transformation for corporate healthcare clients, health systems, providers, pharma and digital health clients in EMEA, Asia Pacific and Emerging Markets.

Engineering degree from CentraleSupélec and a Master of Science in Finance from the Imperial College (UK).

Fabien joined Omnes’s Investment Team in January 2017 and was appointed Director in 2021. He actively invests in TechBio and Deeptech companies and sits at the supervisory board of companies such as SeqOne Genomics, Qubit Pharmaceuticals, Quandela, Sekoia.io.

MBA from Mannheim Business School, Germany, and a Diploma in Computer Science and Business Administration (Business Informatics) from Cooperative State University Karlsruhe, Germany.

Christian joined M Ventures in August 2019 as Head of Strategy and currently serves as a Principal in the Biotechnology team. Prior to joining M Ventures, Christian worked at Merck KGaA, where he focused on impactful strategy-related projects across all business sectors of the Merck Group.

Ph.D. in Chemistry from Stanford University. 25+ years of professional experience in drug discovery and scientific leadership in the pharma industry.

Vincent is the co-inventor of several new antibacterials and oncology drugs put in clinical development. Co-author of more than 50 publications and patent applications, he currently serves as Head of Medicinal Chemistry at Debiopharm.

Graduated from Lausanne Hospitality Management school

Jérôme joined the Private Equity investment company MI3 S.A. in Luxembourg in 2014, where he operates as Investment Manager and Director. Previously, he was the Chief Financial Officer for the Belgian startup Rouge Tomate in Brusselles and New York and then Management Controller for the Groupe Castel in West Africa.

Rafael Gomez-Bombarelli is the Paul M. Cook Career Development Professor at MIT, leading the Learning Matter Lab. He holds a degree in chemistry from Universidad de Salamanca, followed by postdoctoral work at Heriot-Watt and Harvard Universities. His multiple accolades include the Sloan Fellowship, the Camille and Henry Dreyfus Foundation "Machine Learning in the Chemical Sciences and Engineering Award," and the Google Faculty Research Award. He co-founded Calculario, a Harvard spinout, and is former Chief Learning Officer at ZebiAI.

Thierry Masquelin is renowned for creating the Lilly Life Science Studio (L2S2) and the world’s first Automated Synthesis and Purification Lab (ASPL). He has a PhD from the University of Haute Alsace and currently serves as COO of the ASPIRE initiative at the National Center for Advancing Translational Sciences (NCATS). After holding senior positions at Lilly, he joined Recursion Therapeutics as Senior Director, to develop a unified, multi-disciplinary platform to consolidate early drug discovery phases.

Laurent Debussche served as VP Global Head of Oncology Research at Sanofi, where he advanced several first-in-human oncology drug candidates. He has co-authored over 60 international scientific publications and holds several dozen patents. With a PhD in Molecular Biology from Pierre et Marie Curie University (France), Laurent has led innovative research initiatives throughout his career.

Friedrich Rippmann is former Director of Computational Chemistry and Biologics at Merck KGaA. A very early and visionary adopter of AI in the Pharmaceutical industry, he led the integration of AI and machine learning into drug discovery and contributed to the advancement of AI methodology. His groundbreaking efforts in discovering and optimizing lead compounds have revolutionized the application of computational chemistry in Pharma. Currently, he is an independent AI consultant and serves as Director at Combinable.ai.

Dominique Bridon is a seasoned pharmaceutical executive, with expertise spanning oncology, infectious diseases, metabolic, and cardiovascular disorders, Dr. Bridon has been instrumental in developing successful and innovative therapies across multiple areas. Holding senior management positions, including Abbott Laboratories, Ipsen, and Epivax Oncology, as well as several biotechs successfully acquired by larger players, such as Optivia, Enobia, and Syntaxin. Additionally, Dr. Bridon co-founded Conjuchem, which achieved an IPO on the Toronto Stock Exchange and was later acquired.

PhD in organic chemistry, +30 years of experience in Drug Discovery and Medicinal Chemistry.

Alexis contributed to the successful discovery and development of >15 clinical candidates going to Phase I and beyond. Now SVP, Head of Drug Discovery at Iktos.

PhD in Chemistry, +18 years of experience in drug discovery portfolio strategy and management and business development at Novartis.

Formerly VP, and Head of Business Development at Chinook Therapeutics, overseeing all business development aspects until its acquisition by Novartis AG in August 2023. Now, at Iktos, leading the global business development team and contributing to the company’s strategy as a member of the executive committee.

Engineering degree from Ecole Polytechnique and Master’s in Applied Biosciences & Biotechnology from Imperial College London. In charge of strategic planning & corporate development at Iktos.

MS in Materials Sciences & Engineering from Université de Montpellier and MBA in Marketing from Indiana University’s Kelley School of Business. More than 30 years of sales, and business development activities, including more than ten years of successful partnerships with pharmaceutical industries worldwide. Now VP-Head of BD, Sales & Operations, USA

PhD in Pharmaceutical Sciences. 13 years experience in pharma R&D at Astellas Pharma as an expert in computational chemistry and chemoinformatics. Now, Representative Director of Iktos K.K., VP Japan Operations and Business Development at Iktos, leading Iktos’s business expansion in APAC region.

PhD in organic chemistry. Research Associate at the University of Cambridge. Senior Research Scientist at Idenix Pharmaceuticals. Co-founder and Medicinal Chemistry Director at Oxeltis. 20 years of experience in the pharmaceutical industry. Now, Head of Robotics, Iktos.

PhD and post-doc in Bioinformatics. Spearheaded the development of Iktos structure-based generative modeling technology and pipeline. Head of Iktos modeling team.

Master’s in Applied Mathematics and Computer Science. Key contributor to the development of Iktos generative modeling technology. Lead developer of Iktos retrosynthesis technology.

Master’s in Software Engineering. 15 years experience as CTO, successful experience of software product development. In charge of the software development team.

PhD in chemistry. Over 12 years of experience of medicinal chemistry. Project leader in a med chem project that successfully delivered a drug candidate. Now leads the Med Chem team at Iktos.

Pharmacist and PhD in computational structural biology from the University of Strasbourg. In charge of business development activities in Europe

Engineering degree from Ecole polytechnique and MSc at Polytechnique Montreal in Biomedical. In charge of the design and development of data processing pipelines and High performance computing systems for computational chemistry.

Master's degree in IT system expertise. Former developer and infrastructure engineer. In charge of Cloud engineering team at Iktos.

Engineering degree from Ecole Centrale Lyon and Master's degree in Health engineering from Université de Lyon. Spent 10+ years in pharma company as project manager, team manager and operational excellence lead. In charge of operational excellence, processes and transversal projects at Iktos.